Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease
- PMID: 26219979
- PMCID: PMC4602259
- DOI: 10.1136/thoraxjnl-2015-206780
Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease
Abstract
Pneumococcal disease (including community-acquired pneumonia and invasive pneumococcal disease) poses a burden to the community all year round, especially in those with chronic underlying conditions. Individuals with COPD, asthma or who smoke, and those with chronic heart disease or diabetes mellitus have been shown to be at increased risk of pneumococcal disease compared with those without these risk factors. These conditions, and smoking, can also adversely affect patient outcomes, including short-term and long-term mortality rates, following pneumonia. Community-acquired pneumonia, and in particular pneumococcal pneumonia, is associated with a significant economic burden, especially in those who are hospitalised, and also has an impact on a patient's quality of life. Therefore, physicians should target individuals with COPD, asthma, heart disease or diabetes mellitus, and those who smoke, for pneumococcal vaccination at the earliest opportunity at any time of the year.
Keywords: Asthma; Bacterial Infection; COPD Exacerbations; Pneumonia.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Similar articles
-
Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination.Eur J Intern Med. 2017 Jan;37:13-18. doi: 10.1016/j.ejim.2016.09.024. Epub 2016 Oct 15. Eur J Intern Med. 2017. PMID: 27756499 Review.
-
Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence.Int J Infect Dis. 2015 Aug;37:30-5. doi: 10.1016/j.ijid.2015.05.003. Epub 2015 May 19. Int J Infect Dis. 2015. PMID: 25997673 Review.
-
Prevention of pneumonia through vaccination.J Assoc Physicians India. 2013 Jul;61(7 Suppl):38-40. J Assoc Physicians India. 2013. PMID: 24779157 No abstract available.
-
Vaccination in Patients With Heart Disease. How Long Should We Wait?Rev Esp Cardiol (Engl Ed). 2019 Jun;72(6):515. doi: 10.1016/j.rec.2018.08.023. Epub 2018 Oct 3. Rev Esp Cardiol (Engl Ed). 2019. PMID: 30292706 English, Spanish. No abstract available.
-
Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.Expert Rev Vaccines. 2012 Feb;11(2):221-36. doi: 10.1586/erv.11.176. Expert Rev Vaccines. 2012. PMID: 22309670 Review.
Cited by
-
Improving Pneumococcal Vaccination Rates in an Inpatient Pediatric Diabetic Population.Ochsner J. 2022 Fall;22(3):239-243. doi: 10.31486/toj.22.0036. Ochsner J. 2022. PMID: 36189088 Free PMC article.
-
Inhaled Corticosteroids May Not Affect the Clinical Outcomes of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.Tuberc Respir Dis (Seoul). 2024 Jul;87(3):319-328. doi: 10.4046/trd.2023.0176. Epub 2024 Feb 19. Tuberc Respir Dis (Seoul). 2024. PMID: 38369876 Free PMC article.
-
Mortality and costs of pneumococcal pneumonia in adults: a cross-sectional study.J Bras Pneumol. 2019 Oct 17;45(6):e20180374. doi: 10.1590/1806-3713/e20180374. eCollection 2019. J Bras Pneumol. 2019. PMID: 31644703 Free PMC article.
-
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.Hum Vaccin Immunother. 2023 Dec 31;19(1):2177066. doi: 10.1080/21645515.2023.2177066. Epub 2023 Mar 2. Hum Vaccin Immunother. 2023. PMID: 36864601 Free PMC article. Clinical Trial.
-
Age, Pulse, Urea, and Albumin Score: A Tool for Predicting the Short-Term and Long-Term Outcomes of Community-Acquired Pneumonia Patients With Diabetes.Front Endocrinol (Lausanne). 2022 Jun 1;13:882977. doi: 10.3389/fendo.2022.882977. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35721751 Free PMC article.
References
-
- Ludwig E, Unal S, Bogdan M, et al. . Opportunity for healthy ageing: lessening the burden of adult pneumococcal disease in Central and Eastern Europe, and Israel. Cent Eur J Public Health 2012;20:121–5. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical